Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…Abstract Number: 459 • 2015 ACR/ARHP Annual Meeting
The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry
Background/Purpose: Abatacept (ABA) is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). In TURKBIO, Turkish Biologic Registry, data on patient characteristics, diagnosis, previous treatment…Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…Abstract Number: 488 • 2015 ACR/ARHP Annual Meeting
Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Background/Purpose: The sustainability of any regimen is an important factor to consider when selecting therapy for chronic conditions, such as rheumatoid arthritis (RA). Recent reports…Abstract Number: 497 • 2015 ACR/ARHP Annual Meeting
Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, predominantly affecting women in their fifth and sixth decades of life. Although population aging increases the…Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…Abstract Number: 1437 • 2015 ACR/ARHP Annual Meeting
Prevalence of Pain, Its Impact and Management in a Population-Based Cohort of Patients with Rheumatoid Arthritis: Data from the Australian Rheumatology Association Database
Background/Purpose: Despite advances in the treatments available for rheumatoid arthritis (RA), many patients continue to experience musculoskeletal pain. Untreated and under-treated pain are well known to increase…Abstract Number: 1597 • 2015 ACR/ARHP Annual Meeting
Variability in Health Assessment Questionnaire Based on Type of Health Insurance Coverage and Rheumatology Practice
Background/Purpose : Previous studies in rheumatoid arthritis (RA) have shown that patient socioeconomic status (SES) impacts patient prognosis. We hypothesized that public vs. private healthcare…Abstract Number: 2669 • 2015 ACR/ARHP Annual Meeting
Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy
Background/Purpose: AM stiffness is a common yet under-appreciated symptom in RA. The longitudinal impact of AM stiffness has not been previously investigated. This study evaluated…Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry
Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…Abstract Number: 1069 • 2014 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study
Background/Purpose Comorbidity among cancer patients imposes additional risks for premature mortality. The specific effect of rheumatoid arthritis (RA) on survival among cancer patients is unknown.…Abstract Number: 501 • 2014 ACR/ARHP Annual Meeting
Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…Abstract Number: 510 • 2014 ACR/ARHP Annual Meeting
Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept – Results from the National Swedish Rheumatology Quality Register
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…Abstract Number: 418 • 2014 ACR/ARHP Annual Meeting
Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients
Background/Purpose : Morning stiffness is a symptom of rheumatoid arthritis (RA) that is frequently reported and thought to reflect disease activity, but its etiology is…